151 related articles for article (PubMed ID: 10845820)
1. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients.
Abu-Alfa AK; Cruz D; Perazella MA; Mahnensmith RL; Simon D; Bia MJ
Am J Kidney Dis; 2000 Jun; 35(6):1076-82. PubMed ID: 10845820
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance?
Cruz DN; Perazella MA; Abu-Alfa AK; Mahnensmith RL
Am J Kidney Dis; 1996 Oct; 28(4):535-40. PubMed ID: 8840943
[TBL] [Abstract][Full Text] [Related]
3. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients.
Ertürk S; Nergizoğlu G; Ateş K; Duman N; Erbay B; Karatan O; Ertuğ AE
Nephrol Dial Transplant; 1999 Aug; 14(8):1912-6. PubMed ID: 10462270
[TBL] [Abstract][Full Text] [Related]
4. Ace inhibitors and erythropoietin response in hemodialysis patients.
Ertürk S
Am J Kidney Dis; 2000 Oct; 36(4):880. PubMed ID: 11007696
[No Abstract] [Full Text] [Related]
5. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Qureshi IZ; Abid K; Ambreen F; Qureshi AL
Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
[TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin.
Hayashi K; Hasegawa K; Kobayashi S
Kidney Int; 2001 Nov; 60(5):1910-6. PubMed ID: 11703610
[TBL] [Abstract][Full Text] [Related]
7. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
8. Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis.
Schwenk MH; Jumani AQ; Rosenberg CR; Kulogowski JE; Charytan C; Spinowitz BS
Pharmacotherapy; 1998; 18(3):627-30. PubMed ID: 9620114
[TBL] [Abstract][Full Text] [Related]
9. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.
Gaughan WJ; Liss KA; Dunn SR; Mangold AM; Buhsmer JP; Michael B; Burke JF
Am J Kidney Dis; 1997 Oct; 30(4):495-500. PubMed ID: 9328363
[TBL] [Abstract][Full Text] [Related]
10. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
11. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure.
Conlon PJ; Kovalik E; Schumm D; Minda S; Schwab SJ
Ren Fail; 2000; 22(4):435-44. PubMed ID: 10901181
[TBL] [Abstract][Full Text] [Related]
12. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.
Albitar S; Genin R; Fen-Chong M; Serveaux MO; Bourgeon B
Nephrol Dial Transplant; 1998 May; 13(5):1206-10. PubMed ID: 9623555
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
Driver PS
Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
[TBL] [Abstract][Full Text] [Related]
14. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
Harmankaya O; Eran A
Ren Fail; 2002 Mar; 24(2):245-7. PubMed ID: 12071600
[TBL] [Abstract][Full Text] [Related]
15. [The effects of ACE inhibitor treatment and ACE gene polymorphism on erythropoiesis in chronic hemodialysis patients].
Hatano M; Yoshida T; Mimuro T; Kimata N; Tsuchiya K; Sanaka T; Nihei H
Nihon Jinzo Gakkai Shi; 2000 Oct; 42(8):632-9. PubMed ID: 11195399
[TBL] [Abstract][Full Text] [Related]
16. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.).
De Schoenmakere G; Lameire N; Dhondt A; Van Loo A; Van der Goten J; Duym P; Vanholder R
Nephrol Dial Transplant; 1998 Jul; 13(7):1770-5. PubMed ID: 9681726
[TBL] [Abstract][Full Text] [Related]
17. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
[TBL] [Abstract][Full Text] [Related]
18. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
Carlini R; Obialo CI; Rothstein M
Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
[TBL] [Abstract][Full Text] [Related]
19. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.
Charytan C; Goldfarb-Rumyantzev A; Wang YF; Schwenk MH; Spinowitz BS
Am J Nephrol; 1998; 18(6):498-503. PubMed ID: 9845824
[TBL] [Abstract][Full Text] [Related]
20. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients?
Hess E; Sperschneider H; Stein G
Nephrol Dial Transplant; 1996 Apr; 11(4):749-751. PubMed ID: 8671881
[No Abstract] [Full Text] [Related]
[Next] [New Search]
